MedTrace Logo

Study of the Effect of SR57667B in Patients With Alzheimer's Disease

NCT00285025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2006-02-01

No results posted yet for this study

Summary

The primary objective is to demonstrate that SR57667B at the dose of 4 mg/day, in comparison to placebo, decreases the decline in cognitive performance and the global clinical decline over 1 year in patients with mild to moderate AD.

Secondary objectives are to assess the effect of SR57667B on functional decline and its safety/tolerability in patients with mild to moderate AD, and to document plasma concentrations of SR57667 in patients with mild to moderate AD.

Conditions

  • Alzheimer Disease

Interventions

DRUG

SR57667B

Sponsors & Collaborators

Principal Investigators

  • Serge GAUTHIER, MD · Scientific Advisory Committee

  • Jean-Marc ORGOGOZO, MD · Scientific Advisory Committee

  • Philip SCHELTENS, MD · Scientific Advisory Committee

  • Bengt WINBLAD, MD · Scientific Advisory Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2005-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285025 on ClinicalTrials.gov